Maintenance Therapy Post-Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.

acute myeloid leukemia (AML) cellular therapy hematopoietic stem cell transplantation (HSCT) hypometylating agents maintenance therapy post-HSCT in AML targeted drugs

Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
10 Oct 2024
Historique:
received: 11 09 2024
revised: 05 10 2024
accepted: 08 10 2024
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

High-risk acute myeloid leukemia has been associated with a poor outcome. Hematopoietic stem cell transplantation (HSCT) represents the only curative option for eligible patients. Relapse after HSCT is a dramatic event with poor chances of survival. With the aim of reducing the rate of post-HSCT relapse, maintenance treatment has been investigated in this setting. Results from clinical trials suggest an advantage in the use of a maintenance strategy; however, standardized guidelines are not yet available due to the lack of prospective clinical trials. In this review, we have reported the most important strategies adopted as post-HSCT maintenance, highlighting their efficacy, but the current research also opens questions.

Identifiants

pubmed: 39451755
pii: curroncol31100451
doi: 10.3390/curroncol31100451
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

6050-6060

Auteurs

Martina Canichella (M)

Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy.

Matteo Molica (M)

Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, Italy.

Carla Mazzone (C)

Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy.

Paolo de Fabritiis (P)

Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy.
Department of Biomedicina e Prevenzione, Tor Vergata University, 00133 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH